PAOLI, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.044
EU - Europa 478
AS - Asia 130
SA - Sud America 2
Totale 1.654
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.041
IT - Italia 194
IE - Irlanda 89
SE - Svezia 77
HK - Hong Kong 57
PL - Polonia 38
CN - Cina 33
JO - Giordania 30
CH - Svizzera 26
DE - Germania 14
RU - Federazione Russa 9
FI - Finlandia 8
FR - Francia 7
GB - Regno Unito 5
ES - Italia 4
VN - Vietnam 4
CA - Canada 3
SG - Singapore 3
UA - Ucraina 3
BR - Brasile 2
NL - Olanda 2
RO - Romania 2
IN - India 1
MY - Malesia 1
TR - Turchia 1
Totale 1.654
Salva come PNG Salva come JPEG
Città #
Fairfield 191
Ashburn 107
Woodbridge 94
Chandler 93
Dublin 89
Seattle 81
Cambridge 72
Houston 72
Wilmington 61
Florence 45
Warsaw 38
Altamura 37
Hong Kong 37
Lawrence 30
Princeton 28
Bern 26
Ann Arbor 23
Beijing 14
Boston 12
Medford 12
Buffalo 11
Boardman 10
Bremen 10
Rome 10
Moscow 9
Dearborn 6
Frosinone 6
San Diego 6
Shanghai 6
Latina 5
Los Angeles 5
Barcelona 4
Cagliari 4
Dong Ket 4
Falls Church 4
Milan 4
Napoli 4
Norwalk 4
Andover 3
Faenza 3
London 3
Toronto 3
Ancona 2
Burghausen 2
Chengdu 2
Fuzhou 2
Genova 2
Hangzhou 2
Hefei 2
Mountain View 2
Naples 2
New York 2
Parma 2
San Gavino Monreale 2
San Giovanni Valdarno 2
Sant'elpidio A Mare 2
Siena 2
Turin 2
Washington 2
Abenberg 1
Atlanta 1
Bari 1
Bitonto 1
Catanzaro 1
Corato 1
Fiesole 1
Fontevivo 1
Gloucester 1
Hillsboro 1
Iasi 1
Imperia 1
Izmir 1
Jacksonville 1
Kent 1
Kunming 1
Leawood 1
Littleton 1
Malo 1
Marigliano 1
Monteriggioni 1
Monza 1
Ngau Wu Tok 1
Olgiate Comasco 1
Padova 1
Palermo 1
Piacenza 1
Prato 1
Pune 1
Redmond 1
Reggio Emilia 1
Rotterdam 1
Rozzano 1
San Mateo 1
Scandicci 1
Sesto 1
Sesto Fiorentino 1
Shenyang 1
Shenzhen 1
Specchia 1
São Paulo 1
Totale 1.361
Salva come PNG Salva come JPEG
Nome #
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group 123
Sviluppo e gestione di studi clinici indipendenti di Fase I/II nelle Neoplasie Mieloproliferative Croniche 121
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation 114
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis 109
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 105
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 97
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation 97
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms 96
Kaposi Sarcoma in a patient treated with Ruxolitinib 92
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group 87
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 86
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative 86
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs 78
Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms 76
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B 2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 74
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 57
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 39
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 37
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients 36
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study 29
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 28
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 28
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score 10
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 1
Totale 1.706
Salva come PNG Salva come JPEG
Categoria #
all - tutte 5.625
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.625
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201970 0 0 0 0 0 0 0 0 0 0 36 34
2019/2020428 18 11 8 35 53 60 61 57 56 30 24 15
2020/2021264 18 21 30 44 14 10 7 20 27 37 28 8
2021/2022154 5 11 15 4 3 7 5 20 11 6 22 45
2022/2023505 43 96 34 29 29 77 61 28 60 6 15 27
2023/2024211 12 20 24 21 17 24 5 68 6 13 1 0
Totale 1.706